eXoZymes, Inc. — News

eXoZymes Inc. (NASDAQ: EXOZ - Get Free Report)'s stock price dropped 1.1% on Monday. The stock traded as low as $4.60 and last traded at $4.60. Approximately 12,408 shares were traded during trading, an increase of 30% from the average session volume of 9,573 shares. The stock had previously closed at $4.65. Analyst Upgrades and

defenseworld.net - 2026-08-04 02:21:57

Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes. The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.

accessnewswire.com - 2026-07-23 16:15:00

Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules. NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.

accessnewswire.com - 2026-06-24 16:10:00

LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants. The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common stock and one warrant to purchase one additional share of common stock.

accessnewswire.com - 2026-06-17 16:10:00

LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the pricing of its public offering of units, each consisting of two shares of common stock and one common stock purchase warrant. The Company has sold 592,270 shares of common stock together with 296,135 warrants as units, each unit consisting of two shares of common stock and one warrant to purchase one share of common stock.

accessnewswire.com - 2026-06-08 09:00:00